Safety evaluation of tirofiban

Expert Opinion on Drug Safety

Volumn 9, Issue 5, 2010, Pages 801-819

  Valgimigli, Marco ^a   Tebaldi, Matteo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Acute coronary syndrome; GP IIb IIIa inhibitor; Non ST segment elevation myocardial infarction; Platelet; ST segment elevation myocardial infarction; Thrombosis; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; PLACEBO; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HEMATOMA; HEMATURIA; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; MONOTHERAPY; OPTIMAL DRUG DOSE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ASPIRIN; DOUBLE-BLIND METHOD; DRUG RESISTANCE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; MULTICENTER STUDIES AS TOPIC; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTOPENIA; TICLOPIDINE; TYROSINE;

EID: 77955950166     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.507189     Document Type: Review

References (78)

1. British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008. Available from: . ehnheart.org/files/ statistics%202008% 20web-161229A.pdf. [Accessed 30 March 2010]
2. Gibson CM. NRMI and current treatment patterns for ST-elevation myocardial infarction. Am Heart J 2004;148(5):S29-33
3. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999;281(8):707-713
4. Volmink JA, Newton JN, Hicks NR, et al. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group. Heart 1998;80(1):40-44
5. Terkelsen CJ, Lassen JF, Norgaard BL, et al. Reduction of treatment delay in patients with ST-elevation myocardial infarction: impact of pre-hospital diagnosis and direct referral to primary percutanous coronary intervention. Eur Heart J 2005;26(8):770-777
6. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007;28(13):1598-1660
7. Shah PK. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis 2002;44(5):357-368
8. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thrombosis Haemost 1995;74:1-6
9. Theroux P, Fuster V. Acute coronary syndromes. Unstable angina and non-Q wave myocardial infarction. Circulation 1998;97:1195-1206
10. Sakariassen KS, Joss R, Muggli R, et al. Collagen type III induced ex vivo thrombogenesis in humans. Role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 1990;10(2):276-284
11. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003;290(12):1593-1599
12. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344(25):1879-1887
13. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004;109:1223-1225
14. De Luca G, van t Hof AW, de Boer MJ, et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 2004;25(12):1009-1013
15. Nallamothu B, Fox KA, Kennelly BM, et al. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart 2007;93(12):1552-1555
16. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting withST-segment elevation. Eur Heart J 2008;29:2909-2945
17. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001;104:181-186
18. Skyschally A, Erbel R, Heusch G. Coronary microembolisation. Circ J 2003;67:279-286
19. Heusch G, Schulz R, Baumgart D, et al. Coronary microembolisation. Prog Cardiovasc Dis 2001;44(3):217-230
20. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110(11):1392-1397
21. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578
22. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol 2006;48(11):2178-2185
23. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557-567
24. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50(7):e1-e157
25. Antman EM, Hand M, Armstrong PW, et al. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51(2):210-247
26. Phillips DR, Charo IF, Prise LV, et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988;71:831-843
27. Brown DL, Fann CS, Chang CJ. Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction. Cardiovasc Drugs Ther 2000;14(3):253-258
28. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomised trials. JAMA 2005;293:1759-1765
29. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998;97:211-218
30. Tcheng JE, Ellis SG, George BS, et al. Pharmakodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90(4):1757-1764
31. Charo IF, Scarborough RM, DuMee CP, et al. Pharmacodynamics of the GPIIb-IIIa antagonist integrelin: phase I clinical studies in normal healthy volunteers. Circulation 1992;86(Suppl I):I-260
32. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993;88(4 Pt 1):1512-1517
33. Schor K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thrombosis Thrombolysis 2003;15(2):71-80
34. Valgimigli M, Campo G, Peroco G, et al. Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives. Future Cardiol 2006;2(1):17-27
35. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338(21):1498-1505
36. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338(21):1488-1497
37. Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006;47(3):522-528
38. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96(5):1445-1453
39. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344(25):1888-1894
40. Herrmann HC, Swierkosz TA, Kapoor S, et al. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2002;89(11):1293-1297
41. Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89(5):647-650
42. Lakkis N, Lakiss N, Bobek J, Farmer J. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited. Catheter Cardiovasc Interv 2002;56(4):474-477
43. Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002;90:1421-1423
44. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty-The ADVANCE trial. J Am Coll Cardiol 2004;44(1):14-19
45. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention. Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin. Circulation 2009;119:3215-3222
46. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness. the 3T/2R (Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel). J Am Coll Cardiol 2010;55:255-256
47. Van t Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Lancet 2008;372(9638):537-546
48. Hamm CW, van t Hof AW, Dill T, et al. Prehospital tirofiban in ST-elevation myocardial infarction: one-year outcome of ON-TIME-2. American College of Cardiology (ACC) Annual Scientific Sessions, March 2009
49. Danzi GB, Sesana M, Capuano C, et al. Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention. Int J Cardiol 2006;107(2):241-246
50. Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol 2004;94(1):35-39
51. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs. abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293(17):2109-2117
52. Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 2007;50(2):138-145
53. Taglieri N, Saia F, Guiducci V, et al. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban from the Facilitated Angioplasty with Tirofiban or Abciximab FATA Trial). Am J Cardiol 2009;103(6):785-790
54. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008;299(15):1788-1799
55. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomised trial. Eur Heart J 2009. DOI:10.1093/eurheart/ehp/ 376
56. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787
57. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913
58. Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J 2009;30(18):2193-2203
59. Moliterno DJ. Tirofiban novel dosing vs. abciximab with evaluation of clopidogrel and inhibition of thrombin (TENACITY) study. PowerPoint Presentation. Presented at: TCT 2005: Washington, DC; 20 October 2005
60. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330(14):956-961
61. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-1696
62. Eichhofer J, Horlick E, Ivanov J, et al. Decreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: a large single-center experience. Am Heart J 2008;156(5):864-870
63. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289(7):853-863
64. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369(9565):907-919
65. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-2230
66. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-st-segment elevation acute coronary syndromes. Results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;53:1021-1030
67. Nelson MA, Voeltz D, Feit F, et al. Elderly patients with major bleeding or need for transfusion complicating percutaneous coronary intervention have an increased risk of 30-day and 1-year mortality. Circulation 2006;114:11-687
68. Januzzi JL Jr, Sabatine MS, Wan Y, et al. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. Am J Cardiol 2003;91(4):457-461
69. Gafter U, Bessler H, Malachi T, et al. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron 1987;45:207-210
70. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996;27:355-364
71. Liani M, Salvati F, Golato M, et al. Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia. Nephron 1996;68:442-448
72. Attallah N, Yassine L, Fisher K, Yee J. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol 2005;64(6):412-418
73. Khanal S, Smith DE, Safian R, et al. Chronic renal insufficiency and bleeding risk after percutaneous coronary intervention: a continuous rather than a "threshold" relationship. Circulation 2006;114:II-842
74. Januzzi JL Jr, Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002;105(20):2361-2366
75. Aggrastat (tirofiban hydrochloride). Iroko Pharmaceuticals. EU Summary of product characteristics
76. Shanmugam G. Tirofiban and emergency coronary surgery. Eur J Cardiothoracic Surg 2005;28(4):546-550
77. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139:S38-45
78. Dyke CM. Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeons perspective. Am Heart J 1999;138(4 Pt 2):307-316